TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

77 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

69 studies on the map

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder — Vanda Investigational Site, PhoenixACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghCreatine for Depressed Male and Female Methamphetamine Users — Montana State University College of Nursing (Missoula campus), MissoulaA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaTesting the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease — Weill Cornell Medicine, New YorkA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonThe Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety — The Ohio State University, ColumbusMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los AngelesBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder — Wayne State University School of Medicine, Tolan Park Medical Building, DetroitA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) — Connecticut Clinical Research Institute ( Site 0297), BristolA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — University of South Alabama (USA) Physicians Group, MobileA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — UCSF Medical Center at Mission Bay, San FranciscoCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Sun City Clinical Research, GlendaleEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, Columbia